Global Next Generation Sequencing (NGS) Market Size and Forecast to 2030

By end of 2021, the global next-generation sequencing market will be worth USD 4 Billion and is expected to grow at a compound annual growth rate (CAGR) of around 16% during the forecast period 2022-2030. Genome sequencing has been used to understand the spread of Covid-19, and has the potential to understand the impact of interventions and help guide future treatments. The British Consortium for Covid-19 Genomics (COG-U.K.) was established in March 2020 to analyze coronavirus genomes using whole genome sequencing (WGS). The consortium includes Wellcome Sanger Research Institute, NHS, public health institutions and other academic institutions. These groups worked together to map the evolution and spread of the virus.The consortium also aims to understand the viral infection chain to prevent the spread of the virus. Researchers at the University of Liverpool are performing sequencing to analyze the unique genetic code of samples collected from others, and companies like Thermo Fisher and Illumina are preparing to fight epidemics through sequencing. Illumina provided support and technology for tracking and tracking shipments. In addition, the highly competitive global market forces us to develop vaccines and therapeutics to ensure long-term global safety. Key industry players are collaborating with other companies to increase the use of operating systems for research and discovery. For example, in January 2021 Illumina announced a series of cancer partnerships with Merck, Myriad Genetics, Cura Oncology, and Bristol Myers Squibb to expand the use and scope of the TruSight Oncology Global Cancer Test.

APPLICATION INSIGHT:

The Applied Oncology business was the highest in 2020 with over 28%. Next-generation sequencing (NGS) with bioinformatics tools has the potential to revolutionize cancer research, diagnosis and treatment. Advances in NGS technology have led to advances in cancer research and are driving the �molecular age� of cancer. Leading companies such as Illumina continue to develop NGS-based laboratory diagnostic (IVD) solutions for cancer diagnosis. For example, in January 2021 Illumina partnered with Myriad Genetics to develop a new diagnostic test version based on the MyChoice (CDx) collection. This technique combines NGS and related diagnostics to improve the genomic profile of tumor samples. Several other market players also offer NGS solutions to support cancer research. For example, in January 2021, the Merus NV Clinical Stage Immunoecology Society worked with the National Cancer Center in Japan and the Erasmus University Medical Center in the Netherlands to study specific anti-HER2/3 antibodies in solid tumors. As part of that, Merus will support access to NGS testing for small cell lung cancer and pancreatic cancer.

INSIGHT:

Technology led the NGS market in 2020 with a target sales share of over 73%. This technique provides an inexpensive alternative to WGS and enables in-depth exploration of genomic regions. RNA-based targeted sequencing is expected to grow favorably in the coming years due to the growing demand for differential expression assays. In addition, the widespread use of RNA-seq amplicon technology for RNA sequencing helps diagnose schizophrenia, etc. promotes the development of the disease. Apoptosis, cardiotoxicity, cell cycle, p450 and p53 pathways, cardiotoxicity and availability of other custom PAGE expression sets are expected to drive future industry growth, with WGS technology starting in 2021. expected to grow. 2028.. Use WGS to promote development to combat COVID-19. Additionally, companies like Illumina are commercializing microbial WGS as the first NGS method that can be used to monitor infectious disease. This technique can provide higher quality data and faster results. It can also be used to identify, monitor and respond to local outbreaks.

WORKFLOW INSIGHT:

Sequences are an important step in the workflow, so by 2020, the workflow analysis sequence section will account for more than 54% of sales. Indexing also increases income in a capital-intensive way. The more WGS implementations planned, the more monitoring data will be generated in the sequence project. After sequencing, large amounts of data are generated, making analysis difficult. However, there are many tools on the market that address these challenges, such as the Illumina Basespace suite, which can analyze data sequences and provide results in a fraction of the time. We also expanded our data analysis services by acquiring DRAGEN Bio-IT (DRAGEN) and Addico Genome Platform. Other companies such as Genomics and dNexus offer cloud-based operating systems for analyzing and managing large amounts of sequence data.

END USE CONCLUSION:

Universities; end-use research sector will account for the largest share in 2020, with over 53%. The sector is expected to grow steadily in 2021-2028 with CAGR approval by NGS. This solution has been implemented in research projects at universities and research centers. In addition, PhD degrees will receive scholarships. NGS projects are expected to stimulate demand and increase revenues for NGS products and services in the future. In addition, many universities in countries such as Germany and the UK offer NGS programs and biomolecular courses. For example, the University of Wageningen in the Netherlands and Research NGS provide facilities and technologies that can be used in a variety of applications. The university uses equipment and operating systems such as the Illumina HiSeq2500, MiSeq, and PacBioSequel.From 2021 to 2028, clinical research is projected to be the fastest growing end use. This is due to the proliferation of NGS-based diagnostic tests that have been abandoned as part of CLIA and as part of clinically sound applications for NGS solutions. In addition, existing commercial clinical research solutions such as Agilent, Illumina and Thermo Fisher Scientific are expected to enrich the public and provide high growth opportunities for this sector during the forecast period.

REGIONAL INFORMATION:

North America will dominate the global market with a revenue share of 49.77% in 2020. The existence of several clinical laboratories that use NGS to provide genetic testing services has boosted the regional market. In addition, new products developed and launched by major North American companies have driven market growth. For example, in August 2020, Quest Diagnostics launched an automated NGS engine to power Ancestrys consumer genetics product, AncestryHealth. The platform provides genetic risk screening for blood diseases, colon cancer, breast cancer, and heart disease. It is expected that from 2021 to 2028, the Asia-Pacific region will become the fastest growing regional market. It is expected that the existence of local companies such as BGI Genomics and NGS service providers such as First BASE Laboratories Sdn Bhd and Macrogen Asia Pacific Pte Ltd. will promote the development of the Asia-Pacific market. MedGenome Labs Ltd. provides NGS services to more than 5,500 doctors and 1,600 hospitals in South Asia and India.

INSIGHTS:

Large Enterprises and Market Share Outlook This sector is characterized by strong competition among large enterprises. Strategies these companies use to increase their market presence include introducing new operating systems that are faster, smaller, and cheaper. For example, in January 2021 Cerba Research announced two new combinations. PCR based and NGS based. A COVID-19 exploration tool that supports research and development to develop vaccines for infectious diseases, including Covid-19. NGS allows WGS-based testing of respiratory viruses and SARS-CoV-2. In December 2020, Eurofins Genomics launched an optimized, low-cost SARS-CoV-2NGS service to sequence the complete viral genome. Roche launched its KAPA Target Enrichment portfolio for KAPA HyperExome Sequences and Target Enrichment through its research group in May 2020. Accordingly, market sales are expected to increase due to intensifying market competition and supply of new products. Who are the prominent players in the global Next-Generation Sequencing market? IlluminaQIAGENTTermoFisherScientific, Inc. Hoffman-La Roche Game Oxford Nanopore Technologies Genomics GmbHPierianDxDNASTAR, Inc. Eurofins GATC Biotech GmbHPerkin Elmer, Inc. BGIBio-Rad Laboratories, Inc.

REPORT AREA SCOPE:

The report forecasts global, regional and national sales growth and provides an analysis of the latest industry trends in each subsector from 2022-2030. For this study, Kenneth Research Global reports on Next Generation Sequencing. wrote. Based on Technology Applications, Workflows, End Uses and Selected Areas: Technology Forecast (Sales, US$1M, 2022-2030M, 2022-2030) Cancer Diagnosis and Screening Widespread Cancer Cancer Monitoring Genetic Cancer General Diagnostics Other Diagnostics Research Diagnosis Number of Infectious Diseases Neurological Disorders and Other Cases Reproductive Genome Health Monitoring Methods Medicine Genome Workflow Forecast (Revenue, USD 1 Million, 2022-2030), University Research, Clinical Research, Hospitals and Clinics, Medicine and biotechnology labs and other users . "

Geography Analysis:

The report further discusses the market opportunity, compound annual growth rate (CAGR) growth rate, competition, new technology innovations, market players analysis, government guidelines, export and import (EXIM) analysis, historical revenues, future forecasts etc. in the following regions and/or countries:

• North America (U.S. & Canada) Market Size, Y-O-Y Growth, Market Players Analysis & Opportunity Outlook
• Latin America (Brazil, Mexico, Argentina, Rest of Latin America) Market Size, Y-O-Y Growth & Market Players Analysis & Opportunity Outlook
• Europe (U.K., Germany, France, Italy, Spain, Hungary, Belgium, Netherlands & Luxembourg, NORDIC(Finland, Sweden, Norway, Denmark), Ireland, Switzerland, Austria, Poland, Turkey, Russia, Rest of Europe), Poland, Turkey, Russia, Rest of Europe) Market Size, Y-O-Y Growth Market Players Analys  & Opportunity Outlook
• Asia-Pacific (China, India, Japan, South Korea, Singapore, Indonesia, Malaysia, Australia, New Zealand, Rest of Asia-Pacific) Market Size, Y-O-Y Growth & Market Players Analysis & Opportunity Outlook
• Middle East and Africa  (Israel, GCC (Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman), North Africa, South Africa, Rest of Middle East and Africa) Market Size, Y-O-Y Growth Market Players Analysis & Opportunity Outlook

.